Format

Send to

Choose Destination
Cancers (Basel). 2018 Sep 18;10(9). pii: E339. doi: 10.3390/cancers10090339.

Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.

Poggio T1,2, Duyster J3,4,5, Illert AL6,7,8.

Author information

1
Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany. teresa.poggio@uniklinik-freiburg.de.
2
Faculty of Biology, Albert Ludwigs University of Freiburg, 79104 Freiburg, Germany. teresa.poggio@uniklinik-freiburg.de.
3
Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany. justus.duyster@uniklinik-freiburg.de.
4
German Cancer Consortium (DKTK) Partner Site Freiburg, 79106 Freiburg, Germany. justus.duyster@uniklinik-freiburg.de.
5
German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. justus.duyster@uniklinik-freiburg.de.
6
Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany. lena.illert@uniklinik-freiburg.de.
7
German Cancer Consortium (DKTK) Partner Site Freiburg, 79106 Freiburg, Germany. lena.illert@uniklinik-freiburg.de.
8
German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. lena.illert@uniklinik-freiburg.de.

Abstract

T cell non-Hodgkin lymphoma (T-NHL) is a rare and heterogeneous group of neoplasms of the lymphoid system. With the exception of a few relatively indolent entities, T-NHL is typically aggressive, treatment resistant, and associated with poor prognosis. Relatively few options with proven clinical benefit are available for patients with relapsed or refractory disease. Immunotherapy has emerged as a promising treatment for the management of patients with hematological malignancies. The identification of tumor antigens has provided a large number of potential targets. Therefore, several monoclonal antibodies (alemtuzumab, SGN-30, brentuximab vedotin, and mogamulizumab), directed against tumor antigens, have been investigated in different subtypes of T-NHL. In addition to targeting antigens involved in cancer cell physiology, antibodies can stimulate immune effector functions or counteract immunosuppressive mechanisms. Chimeric antigen receptor (CAR)-T cells directed against CD30 and immune checkpoint inhibitors are currently being investigated in clinical trials. In this review, we summarize the currently available clinical evidence for immunotherapy in T-NHL, focusing on the results of clinical trials using first generation monoclonal antibodies, new immunotherapeutic agents, immune checkpoint inhibitors, and CAR-T cell therapies.

KEYWORDS:

T cell non-Hodgkin lymphoma (T-NHL); brentuximab vedotin; checkpoint inhibitors; chimeric antigen receptor (CAR)-T cell; monoclonal antibodies

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center